Dhampur Bio Organics Ltd

Execution of Technology Licensing Agreement with Planetary SA, Switzerland

Main Body

Dhampur Bio Organics Limited (DBO) has entered into a Technology Licensing Agreement with Planetary SA, Switzerland on October 19, 2026 at 2:30 pm (IST) for the exclusive production of Mycoprotein in India. This agreement follows a non-binding term sheet executed on January 21, 2026.

Key Terms of Agreement:

  • Construction and operation of Mycoprotein production infrastructure by DBO under a synergetic license-based collaboration model
  • Planetary will serve as technology provider and off-taker of Mycoprotein and related products
  • DBO will be the manufacturer and supplier of Mycoprotein and related products
  • Licensing Fee/Royalty: 10% of after-tax revenue as defined in the Agreement, paid quarterly by DBO to Planetary
  • One-Time Launch Fee: Planetary will charge DBO for engineering, launch, installation, commissioning, process training and handover support on an open book basis until completion, as mutually agreed

Scope of Business Operation:

  • The technology license enables Mycoprotein production using sugar and molasses as feedstock
  • The manufacturing will be undertaken in India
  • Planetary is a Switzerland-based company

Key Obligations:

  • Planetary's obligations: Grant license to specified intellectual property and licensed services; provide engineering, launch, installation, commissioning and initial training support; maintain and enforce licensed intellectual property; provide agreed technical support
  • DBO's obligations: Use licensed intellectual property only for the project and at approved facility; payment of fees and royalties; compliance with confidentiality, access-control, audit, reporting and intellectual-property protection obligations; obtaining required approvals

Term: The agreement is for an initial term of 10 years from the Effective Date, renewable for successive 5-year terms upon mutual written agreement.

Rationale and Benefits:

  • The technology has synergy with DBO's existing business and represents a forward integration step
  • Sugar and molasses will act as feedstock for Mycoprotein production
  • Introduction of a new revenue stream for the Company
  • Expected increase in profitability

Future Arrangements:

  • Parties plan to execute a commercialization and offtake agreement
  • Parties plan to establish a Joint Venture Company through a joint venture agreement to undertake commercialization and offtake of Mycoprotein in India

Regulatory Compliance:

  • This arrangement does not involve any related party transaction
  • Disclosure made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Other Key Announcements

No additional material announcements were disclosed in this filing.